Association Between Social Vulnerability and SARS-CoV-2 Seroprevalence in Specimens Collected From Commercial Laboratories, United States, September 2021-February 2022

Overview

Journal Public Health Rep

Publisher Sage Publications

Specialty Public Health

Date 2024 Feb 15

PMID 38357883

Authors

Tina J Benoit

Yun Kim

Yangyang Deng

Zheng Li

Lee Harding

Ryan Wiegand

Xiaoyi Deng

Jefferson M Jones

Iachan Ronaldo

Kristie E N Clarke

Affiliations

Soon will be listed here.

Abstract

Objective: We conducted a national US study of SARS-CoV-2 seroprevalence by Social Vulnerability Index (SVI) that included pediatric data and compared the Delta and Omicron periods during the COVID-19 pandemic. The objective of the current study was to assess the association between SVI and seroprevalence of infection-induced SARS-CoV-2 antibodies by period (Delta vs Omicron) and age group.

Methods: We used results of infection-induced SARS-CoV-2 antibody assays of clinical sera specimens (N = 406 469) from 50 US states from September 2021 through February 2022 to estimate seroprevalence overall and by county SVI tercile. Bivariate analyses and multilevel logistic regression models assessed the association of seropositivity with SVI and its themes by age group (0-17, ≥18 y) and period (Delta: September-November 2021; Omicron: December 2021-February 2022).

Results: Aggregate infection-induced SARS-CoV-2 antibody seroprevalence increased at all 3 SVI levels; it ranged from 25.8% to 33.5% in September 2021 and from 53.1% to 63.5% in February 2022. Of the 4 SVI themes, socioeconomic status had the strongest association with seroprevalence. During the Delta period, we found significantly more infections per reported case among people living in a county with high SVI (odds ratio [OR] = 2.76; 95% CI, 2.31-3.21) than in a county with low SVI (OR = 1.65; 95% CI, 1.33-1.97); we found no significant difference during the Omicron period. Otherwise, findings were consistent across subanalyses by age group and period.

Conclusions: Among both children and adults, and during both the Delta and Omicron periods, counties with high SVI had significantly higher SARS-CoV-2 antibody seroprevalence than counties with low SVI did. These disparities reinforce SVI's value in identifying communities that need tailored prevention efforts during public health emergencies and resources to recover from their effects.

Citing Articles

Association Between County-Level Social Vulnerability and Vaccine-Related Attitudes and Hesitancy Toward COVID-19 Vaccination in the United States.

Kim Y, Iachan R, Boyle J, Deng Y Vaccines (Basel). 2025; 12(12.

PMID: 39772030 PMC: 11680208. DOI: 10.3390/vaccines12121368.

References

Patel Murthy B, Sterrett N, Weller D, Zell E, Reynolds L, Toblin R . Disparities in COVID-19 Vaccination Coverage Between Urban and Rural Counties - United States, December 14, 2020-April 10, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(20):759-764. PMC: 8136424. DOI: 10.15585/mmwr.mm7020e3. View

Islam S, Nayak A, Hu Y, Mehta A, Dieppa K, Almuwaqqat Z . Temporal trends in the association of social vulnerability and race/ethnicity with county-level COVID-19 incidence and outcomes in the USA: an ecological analysis. BMJ Open. 2021; 11(7):e048086. PMC: 8300549. DOI: 10.1136/bmjopen-2020-048086. View

Wiegand R, Deng Y, Deng X, Lee A, Meyer 3rd W, Letovsky S . Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022. Lancet Reg Health Am. 2022; 18:100403. PMC: 9716971. DOI: 10.1016/j.lana.2022.100403. View

Li Z, Lewis B, Berney K, Hallisey E, Williams A, Whiteman A . Social Vulnerability and Rurality Associated With Higher Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection-Induced Seroprevalence: A Nationwide Blood Donor Study-United States, July 2020-June 2021. Clin Infect Dis. 2022; 75(1):e133-e143. PMC: 8903418. DOI: 10.1093/cid/ciac105. View

Clarke K, Jones J, Deng Y, Nycz E, Lee A, Iachan R . Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(17):606-608. PMC: 9098232. DOI: 10.15585/mmwr.mm7117e3. View

Dalstra J, Kunst A, Borrell C, Breeze E, Cambois E, Costa G . Socioeconomic differences in the prevalence of common chronic diseases: an overview of eight European countries. Int J Epidemiol. 2005; 34(2):316-26. DOI: 10.1093/ije/dyh386. View

Stringhini S, Carmeli C, Jokela M, Avendano M, Muennig P, Guida F . Socioeconomic status and the 25 × 25 risk factors as determinants of premature mortality: a multicohort study and meta-analysis of 1·7 million men and women. Lancet. 2017; 389(10075):1229-1237. PMC: 5368415. DOI: 10.1016/S0140-6736(16)32380-7. View

Torres-Torres J, Martinez-Portilla R, Espino-Y-Sosa S, Estrada-Gutierrez G, Solis-Paredes J, Villafan-Bernal J . Comorbidity, poverty and social vulnerability as risk factors for mortality in pregnant women with confirmed SARS-CoV-2 infection: analysis of 13 062 positive pregnancies including 176 maternal deaths in Mexico. Ultrasound Obstet Gynecol. 2021; 59(1):76-82. PMC: 8662032. DOI: 10.1002/uog.24797. View

Barry V, Dasgupta S, Weller D, Kriss J, Cadwell B, Rose C . Patterns in COVID-19 Vaccination Coverage, by Social Vulnerability and Urbanicity - United States, December 14, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(22):818-824. PMC: 8174677. DOI: 10.15585/mmwr.mm7022e1. View

10.

Takahashi T, Ellingson M, Wong P, Israelow B, Lucas C, Klein J . Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020; 588(7837):315-320. PMC: 7725931. DOI: 10.1038/s41586-020-2700-3. View

11.

Neelon B, Mutiso F, Mueller N, Pearce J, Benjamin-Neelon S . Spatial and temporal trends in social vulnerability and COVID-19 incidence and death rates in the United States. PLoS One. 2021; 16(3):e0248702. PMC: 7990180. DOI: 10.1371/journal.pone.0248702. View

12.

Donders A, van der Heijden G, Stijnen T, Moons K . Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006; 59(10):1087-91. DOI: 10.1016/j.jclinepi.2006.01.014. View

13.

Peluso M, Takahashi S, Hakim J, Kelly J, Torres L, Iyer N . SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021; 7(31). PMC: 8324059. DOI: 10.1126/sciadv.abh3409. View

14.

Murhekar M, Clapham H . COVID-19 serosurveys for public health decision making. Lancet Glob Health. 2021; 9(5):e559-e560. PMC: 8049585. DOI: 10.1016/S2214-109X(21)00057-7. View

15.

Cuadros D, Miller F, Awad S, Coule P, MacKinnon N . Analysis of Vaccination Rates and New COVID-19 Infections by US County, July-August 2021. JAMA Netw Open. 2022; 5(2):e2147915. PMC: 8832175. DOI: 10.1001/jamanetworkopen.2021.47915. View

16.

Yang H, Costa V, Racine-Brzostek S, Acker K, Yee J, Chen Z . Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021; 4(3):e214302. PMC: 7985726. DOI: 10.1001/jamanetworkopen.2021.4302. View

17.

Jung J, Kim J, Park H, Park S, Lim J, Lim S . Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Netw Open. 2022; 5(5):e2213606. PMC: 9131744. DOI: 10.1001/jamanetworkopen.2022.13606. View

18.

Liu S, Morin S, Bourand N, DeClue I, Delgado G, Fan J . Social Vulnerability and Risk of Suicide in US Adults, 2016-2020. JAMA Netw Open. 2023; 6(4):e239995. PMC: 10134005. DOI: 10.1001/jamanetworkopen.2023.9995. View

19.

Brodersen T, Rostgaard K, Lau C, Juel K, Erikstrup C, Nielsen K . The healthy donor effect and survey participation, becoming a donor and donor career. Transfusion. 2022; 63(1):143-155. PMC: 10107247. DOI: 10.1111/trf.17190. View

20.

Yee C, Cunningham S, Ickovics J . Application of the Social Vulnerability Index for Identifying Teen Pregnancy Intervention Need in the United States. Matern Child Health J. 2019; 23(11):1516-1524. DOI: 10.1007/s10995-019-02792-7. View